PlainPharmaWatch

CMS Open Payments · Tool

Zimvie Inc. vs Coloplast Corp

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Coloplast Corp has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 246, versus 59 for the other company. Its single largest recorded recipient represents 12.8% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Zimvie Inc.
HHI 59 · top recipient 3.8%
Ranked #1,749 of 1,838 companies by HHI
Coloplast Corp
HHI 246 · top recipient 12.8%
Ranked #1,514 of 1,838 companies by HHI

Payment Overview

Company A

Zimvie Inc.

Total Payments
$5.9M
% of Industry
0.0%
Transactions
45,687
Avg per Transaction
$129.90
Recipients
45,653
Avg per Recipient
$130.00
Payment Types
6
Top Payment Type
Consulting Fee
Company B

Coloplast Corp

Total Payments
$6.0M
% of Industry
0.0%
Transactions
19,420
Avg per Transaction
$308.83
Recipients
19,137
Avg per Recipient
$313.40
Payment Types
6
Top Payment Type
Consulting Fee

Highlighted values indicate the higher figure for each metric.

Total payments compared

Zimvie Inc. vs Coloplast Corp - total reported payments in CMS Open Payments PY2024

Coloplast Corp$6.0MZimvie Inc.$5.9M

General Payment Types Breakdown

Category shares use each company's General Payments total, not the all-tracks (General + Research + Ownership) hero figure.

Zimvie Inc.

Consulting Fee $2.0M

36.2%

Food and Beverage $1.7M

29.9%

Travel and Lodging $1.3M

23.9%

Education $421.8K

7.5%

Debt Forgiveness $131.7K

2.3%

Space Rental or Facility Fees $10.0K

0.2%

Coloplast Corp

Consulting Fee $1.8M

52.8%

Food and Beverage $767.1K

22.6%

Travel and Lodging $453.9K

13.4%

Grant $319.9K

9.4%

Debt Forgiveness $33.9K

1.0%

Royalty or License $26.9K

0.8%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Zimvie Inc.

  1. 1

    BRUCE OUELLETTE

    $215,715.57 · 226 txns

  2. 2

    AMAR KATRANJI

    $135,669.49 · 154 txns

  3. 3

    Jonathan Esquivel

    $108,883.85 · 169 txns

  4. 4

    STEVEN LOCASCIO

    $104,951.98 · 149 txns

  5. 5

    JASON KIM

    $100,435.71 · 148 txns

Coloplast Corp

  1. 1

    PAUL E. PERITO

    $435,478.69 · 124 txns

  2. 2

    University Of Washington Med Ctr

    $141,841.00 · 1 txns

  3. 3

    Montefiore Medical Center

    $100,000.00 · 1 txns

  4. 4

    Uci Medical Center

    $74,800.00 · 1 txns

  5. 5

    VINCENT LUCENTE

    $71,557.61 · 66 txns

Summary Comparison

Metric Zimvie Inc. Coloplast Corp
Total Payments $5.9M $6.0M
% of Industry Total 0.0% 0.0%
Transaction Count 45,687 19,420
Avg per Transaction $129.90 $308.83
Recipient Count 45,653 19,137
Avg per Recipient $130.00 $313.40
Payment Type Count 6 6
Top Payment Type Consulting Fee Consulting Fee

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.